Nancy L Bartlett

50PUBLICATIONS
300CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Sep 27, 2026
Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.

|Mar 23, 2026
From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma.

Manali Kamdar, Nancy L Bartlett

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Dec 29, 2025
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Jeremy S Abramson, David J Straus, Nancy L Bartlett

|Aug 19, 2025
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani

Pageof 9

Frequent Collaborators

9 joint publications

Brad S Kahl

9 joint publications

Marcus P Watkins

8 joint publications

Neha Mehta-Shah

7 joint publications

Lihua Elizabeth Budde